CA3220176A1 - Composes contenant un peptide - Google Patents

Composes contenant un peptide Download PDF

Info

Publication number
CA3220176A1
CA3220176A1 CA3220176A CA3220176A CA3220176A1 CA 3220176 A1 CA3220176 A1 CA 3220176A1 CA 3220176 A CA3220176 A CA 3220176A CA 3220176 A CA3220176 A CA 3220176A CA 3220176 A1 CA3220176 A1 CA 3220176A1
Authority
CA
Canada
Prior art keywords
arg
lys
compound
pharmaceutically acceptable
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3220176A
Other languages
English (en)
Inventor
Istvan Mandity
Laszlo Molnar
Orsolya Basa-Denes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tavanta Therapeutics Hungary Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3220176A1 publication Critical patent/CA3220176A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le domaine de la thérapie humaine. En particulier, la présente invention concerne un nouveau transporteur d'ions chlorure à base de peptide synthétique et des compositions de celui-ci, ainsi que des méthodes de traitement, de réduction, d'inhibition ou de régulation de maladies associées au canal ionique chlorure.
CA3220176A 2021-05-31 2022-05-31 Composes contenant un peptide Pending CA3220176A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195083P 2021-05-31 2021-05-31
US63/195,083 2021-05-31
PCT/EP2022/064826 WO2022253861A1 (fr) 2021-05-31 2022-05-31 Composés contenant un peptide

Publications (1)

Publication Number Publication Date
CA3220176A1 true CA3220176A1 (fr) 2022-12-08

Family

ID=82117438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3220176A Pending CA3220176A1 (fr) 2021-05-31 2022-05-31 Composes contenant un peptide

Country Status (2)

Country Link
CA (1) CA3220176A1 (fr)
WO (1) WO2022253861A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191263A1 (fr) * 2015-05-22 2016-12-01 Trustees Of Dartmouth College Thérapie et nécessaire pour la prévention et le traitement de la fibrose kystique
AU2020396471A1 (en) * 2019-12-06 2022-06-23 Tavanta Therapeutics Hungary Incorporated Peptide-based synthetic chloride ion transporters

Also Published As

Publication number Publication date
WO2022253861A1 (fr) 2022-12-08

Similar Documents

Publication Publication Date Title
ES2628465T3 (es) Derivados deuterados de ivacaftor
Di Natale et al. Nucleophosmin contains amyloidogenic regions that are able to form toxic aggregates under physiological conditions
US10420738B2 (en) Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction
JP6706020B2 (ja) 視覚障害を処置する組成物と方法
US20140296164A1 (en) Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
US12048676B2 (en) Agents for reversing toxic proteinopathies
CA3160919A1 (en) Peptide-based synthetic chloride ion transporters
US20260001924A1 (en) Nemo coiled coil mimics and methods of using same
CN103946232B (zh) 抗淀粉样蛋白的ɑ‑螺旋阻断超小肽疗法
EP4522195A2 (fr) Compositions de traitement par lipides thérapeutiques et méthodes de traitement de la dégénérescence maculaire liée à l'âge
WO2022253861A1 (fr) Composés contenant un peptide
WO2023143777A1 (fr) Transporteurs d'ion chlorure synthétique à base de peptides
WO2017187274A1 (fr) Procédés et compositions destinés à modifier l'activité régulatrice de la conductance transmembranaire d'une fibrose kystique
Dal Cortivo et al. Protein delivery to the eye: assessing therapeutic potential across inner and outer retina
EP3438120A1 (fr) Peptide neuroprotecteur
WO2021113743A1 (fr) Inhibiteurs de rpn13 à petites molécules ayant des propriétés antitumorales
US20230399361A1 (en) Macrocyclic peptides
AU2015234367A1 (en) Compositions and methods of use for cell targeted inhibitors of the cystic fibrosis transmembrane regulator associated ligand
WO2025085624A1 (fr) Inhibiteurs d'interactions rab-rilpl et leurs utilisations

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251117

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713